image: Antigen presenting cells capture tumour antigen within the tumour microenvironment and migrate to tumour-draining lymph nodes where they prime tumour-reactive T cells. Tumour-reactive T cells then migrate to the tumour microenvironment where they exert anti-tumour effector functions. TIL: Tumour-Infiltrating Lymphocyte.
Credit: Professor Tao Dong Team, University of Oxford, Oxford, UK Image source link: https://link.springer.com/article/10.1007/s44466-025-00007-z#article-info
T cells play central roles in the adaptive immune response against cancer. Their functional inactivation is a primary driver of tumor progression, making the reactivation of T cell function a main goal in immunotherapy. The review details how T cells specifically recognize and eliminate malignant cells by engaging tumor antigen peptides presented by MHC molecules.
“T cells can specifically recognize tumor antigen epitopes presented by MHC molecules to clear malignant tumor cells. The targets that can be recognized by T cells in tumors mainly include two types”, the authors point out. Highly immunogenic, tumor-specific "neoantigens" derived from somatic mutations, and more widely shared "tumor-associated antigens" that are overexpressed in cancers.
The review also illustrates how tumors evade this immune surveillance through multiple mechanisms, including suppressing T cell activation, inducing T cell exhaustion within the immunosuppressive tumor microenvironment, undergoing immunoediting to lose target antigens, and creating physical barriers to T cell infiltration.
The team further provides a detailed discussion on the three major strategies of T cell-mediated immunotherapy:
- Antibody-based therapies, such as immune checkpoint inhibitors that block inhibitory signals and bispecific T cell engagers that redirect T cells to tumors.
- Adoptive Cell Transfer (ACT), including Tumor-Infiltrating Lymphocyte (TIL) therapy, and genetically engineered CAR-T and TCR-T cell therapies, which have shown breakthrough success in hematological and solid malignancies, respectively.
- Cancer vaccines, designed to prime and boost endogenous T cell responses against tumor antigens.
"No single immunotherapy modality is sufficient to address the complex challenges of tumor heterogeneity, the immunosuppressive microenvironment, and on-target/off-tumor toxicities," explains Professor Dong. "The future lies in rationally designed combination therapies that integrate these approaches."
The review identifies two critical frontiers for current research on immunotherapy: first, the discovery of more precise tumor antigens and the establishment of corresponding T cell receptor libraries to develop broader, more specific therapies; second, a deeper mechanistic understanding of T cell biology to identify key functional subsets and biomarkers for improved patient stratification, and ultimately improving the response rate of tumor immunotherapy.
This work provides a robust framework of T cell-mediated immunity and immunotherapy for researchers and clinicians, outlining a clear path toward more effective and durable immunotherapies for cancer patients.
***
Reference
DOI: 10.1007/s44466-025-00007-z
About Immunity & Inflammation
Immunity & Inflammation is a newly launched open-access journal co-published by the Chinese Society for Immunology and Springer Nature under the leadership of Editors-in-Chief Prof. Xuetao Cao and Prof. Jules A. Hoffmann. Immunity & Inflammation aims to publish major scientific questions and cutting-edge advances that explore groundbreaking discoveries and insights across the spectrum of immunity and inflammation, from basic science to translational and clinical research.
Website: https://link.springer.com/journal/44466
About Authors
Tao Dong
Professor Tao Dong is the Ita Askonas Professor of Translational Immunology at the Nuffield Department of Medicine, University of Oxford, and the UK Director of the Chinese Academy of Medical Sciences (CAMS) Oxford Institute. She leads the T Cell Laboratory at the Medical Research Council (MRC) Human Immunology Unit, University of Oxford. Her research focuses on the function of antigen-specific cytotoxic T cells, utilizing advanced single- and multi-omics technologies alongside T cell functional assessment platforms to investigate the critical role of T cells in controlling viral infections and cancer progression.
Adam Bates
Dr. Adam Bates is a Postdoctoral Research Scientist in Professor Tao Dong's group at the Chinese Academy of Medical Sciences Oxford Institute. His research aims to clarify the immune response mechanisms of CD8+ T cells in non-small cell lung cancer (NSCLC). By utilizing advanced technologies such as single-cell RNA and T cell receptor (TCR) sequencing, along with spatial transcriptomics, he seeks to identify T cell populations capable of recognizing and attacking tumors without exhibiting classical exhaustion features. This work lays a solid foundation for developing next-generation anti-tumor immunotherapies.
Funding information
This work was supported by Chinese Academy of Medical Sciences Innovation Fund (2024-I2M-2-001-1) and UK Medical Research Council (MR/Y015347/1).
Method of Research
Systematic review
Subject of Research
Not applicable
Article Title
Leveraging T cells for cancer immunotherapy
Article Publication Date
21-Oct-2025
COI Statement
The corresponding author Tao Dong is a member of the Editorial Board of the journal Immunity & Inflammation. However, she was not involved in the peer review or decision-making process for this manuscript. The authors declare no other competing interests.